102例肝癌患者介入治疗后生存情况及影响因素

目的分析肝癌患者介入治疗后生存情况及其预后相关因素。方法采用多因素回归模型分析102例接受介入治疗的肝癌患者的预后与各项临床特征的相关性。结果肝癌患者中位生存时间为20个月,平均生存（24．95±3．65）个月,1年生存率为63．73％,2年生存率为42．86％,3年生存率为25．49％,5年生存率为7．84％;Cox多因素回归分析结果,显示年龄、Child分级、合并门脉癌栓（β=0．857,OR=2．356）、肿瘤病灶病理分型的恶性程度高（β=0．672,OR=1．958）的患者预后较差,而治疗方式（届=0．525,OR=1．690）较为彻底的患者预后较好。结论肝癌患者介入治疗后的长期生存的总体情况较好,高龄、Child分级低、合并门脉癌栓、肿瘤病灶病理分型的恶性程度高的患者预后较差,而治疗较为彻底的患者预后较好。

Evaluation of Survival and Prognostic Factors of 102 Cases of Primary Hepatic Carcinoma Treated with Interventional Therapy

Objective To evaluate smvival and related prognostic factors of primary hepatic carcinoma patients treated with interventional therapy. Methods 102 patients with primary hepatic carcinoma treated with interventional therapy were selected as the study object. The Coxg regression analysis model was used to analyse the factors affecting the prognosis and clinical features during the 5-year follow-up. Results The median survival time of hepatic carcinoma patients was 20 months and mean survival time was（24.05 ±3.65 ） months. The survival rates of 1,2,3,5 years were 63.73% ,42.86% ,25.49% and 7.84% ,respectively. Multivafiable analysis revealed that significant prognostic factors were age, Child classification, portal cancerous thrombus and pathological types of tumors. Conclusion Long-term survival of hepatocellular carcinoma patients after interventional therapy is good. Patients with advanced age, low Child classification, portal cancerous thrombus have poor prognosis, while patients accept thorough treatment have a good prognosis.